We narrowed to 6,732 results for: pAAV

#98932-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#217676-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL (#217676). In addition to the viral particles, you will also receive purified pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL plasmid DNA. EF1a-driven, Cre-dependent expression of GtACR2 and soma-targeted Voltron2 (ORCHID). These AAV preparations are suitable purity for injection into animals.

Joseph Raimondo

Selfe et al Nat Commun. 2024 Oct 16;15(1):8913. doi:

Feb. 9, 2026

Academic Institutions and Nonprofits only

#58379-AAV8

Ready-to-use AAV8 particles produced from pAAV/D374Y-hPCSK9 (#58379). In addition to the viral particles, you will also receive purified pAAV/D374Y-hPCSK9 plasmid DNA. hAAT-driven expression of mutant (D374Y) human PCSK9. These AAV preparations are suitable purity for injection into animals.

Jacob Bentzon

Bjorklund et al Circ Res. 2014 May 23;114(11):1684-9. do

Feb. 6, 2026

Academic Institutions and Nonprofits only

#213944-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#20299-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA (#20299). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#122063-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-ChrimsonR-GFP (#122063). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-ChrimsonR-GFP plasmid DNA. EF1a-driven expression of ChrimsonR-GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#121539-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Aug. 7, 2025

Academic Institutions and Nonprofits only

#163489-AAV1

Ready-to-use AAV1 particles produced from AiP1051-pAAV-Synapsin promoter-oNigri-WPRE-hGHpA (#163489). In addition to the viral particles, you will also receive purified AiP1051-pAAV-Synapsin promoter-oNigri-WPRE-hGHpA plasmid DNA. Syn-driven expression of codon-optimized Nigri recombinase. These AAV preparations are suitable purity for injection into animals.

Tanya Daigle, Allen Institute for Brain Science

Aug. 6, 2025

Academic Institutions and Nonprofits only

#230681-AAV5

Ready-to-use AAV5 particles produced from AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA (#230681). In addition to the viral particles, you will also receive purified AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA plasmid DNA. minBG-driven expression of iCre recombinase in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 6, 2025

Academic Institutions and Nonprofits only

#214857-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) (#214857). In addition to the viral particles, you will also receive purified AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) plasmid DNA. minBG-driven expression of jGCaMP8s in striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Jan. 27, 2025

Academic Institutions and Nonprofits only

#214856-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14360: pAAV-AiE0779m_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4360) (#214856). In addition to the viral particles, you will also receive purified AiP14360: pAAV-AiE0779m_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4360) plasmid DNA. minBG-driven expression of jGCaMP8s in striatal direct pathway medium spiny neurons (D1 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Jan. 27, 2025

Academic Institutions and Nonprofits only

#128485-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-iSeroSnFR-Nlgn (#128485). In addition to the viral particles, you will also receive purified pAAV-CAG-iSeroSnFR-Nlgn plasmid DNA. CAG-driven expression of a fluorescent reporter for serotonin (localized to dendrites). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Unger et al Cell. 2020 Dec 12. pii: S0092-8674(20)31

Feb. 27, 2024

Academic Institutions and Nonprofits only

#111261-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6m (#111261). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6m plasmid DNA. Synapsin-driven expression of calcium sensor GCaMP6m in axons. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#100835-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

July 8, 2020

Academic Institutions and Nonprofits only

#100840-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.GCaMP6m.WPRE.SV40 (#100840). In addition to the viral particles, you will also receive purified pAAV.CAG.GCaMP6m.WPRE.SV40 plasmid DNA. CAG-driven GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 19, 2018

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#213829-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#50474-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hM3D(Gq)-mCherry (#50474). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM3D(Gq)-mCherry plasmid DNA. hSyn-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 21, 2024

Academic Institutions and Nonprofits only

#83900-AAV5

Ready-to-use AAV5 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 25, 2023

Academic Institutions and Nonprofits only